Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The Proteomic Architecture of Neural and Glioblastoma Stem Cells

FY 2017-18

Summary
Glioblastoma (GBM) is the most malignant form of brain cancer, limiting most patients to 12 months of survival time despite aggressive treatment. Previously thought to be a homogeneous mass, it is now understood that the cell population in tumours is diverse and includes a unique subpopulation that drives cancer formation and progression. Within GBM, these specialized cells are termed glioblastoma stem cells (GSCs) as they share similar developmental and regenerative properties with normal stem cells. More importantly, these GSCs are highly resistant to traditional therapies and thus, examining their biological properties may identify new ways to target the mechanisms that spur GBM growth. Much of our understanding of GBM is from a genomics perspective, but recent advances in a technology known as mass spectrometry (MS) now allows researchers to comprehensively analyze the protein makeup (proteomics) of tumours. Because proteins execute the majority of cellular function and their activity ultimately influences disease behaviour, proteomics represents a refined approach to investigating the role of GSCs in GBMs. To date, an extensive, comparative analysis of the GBM and GSC proteomes with parallel populations of normal neural stem cells has yet to be completed. By using an optimized MS workflow, I will conduct a thorough screen to identify the proteins and pathways critical to GBM and GSC growth. These protein candidates will then be tested for their potential as therapeutic targets in independent validation experiments. Ultimately, this proposal aims to conduct an informative, protein-based analysis of GSCs in the context of GBMS to define new proteins and pathways for the development of more effective, GSC-specific therapies.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386471
Name
Kao Jennifer
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Proteomic Architecture of Neural and Glioblastoma Stem Cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Stem Cells; Glioblastoma; Mass Spectrometry; Neural Stem Cells; Neurogenesis; Personalized Medicine; Phosphoproteomics; Precision Therapy; Proteomics; Subventricular Zone
Abstract
Glioblastoma (GBM) is the most malignant form of brain cancer, limiting most patients to 12 months of survival time despite aggressive treatment. Previously thought to be a homogeneous mass, it is now understood that the cell population in tumours is diverse and includes a unique subpopulation that drives cancer formation and progression. Within GBM, these specialized cells are termed glioblastoma stem cells (GSCs) as they share similar developmental and regenerative properties with normal stem cells. More importantly, these GSCs are highly resistant to traditional therapies and thus, examining their biological properties may identify new ways to target the mechanisms that spur GBM growth. Much of our understanding of GBM is from a genomics perspective, but recent advances in a technology known as mass spectrometry (MS) now allows researchers to comprehensively analyze the protein makeup (proteomics) of tumours. Because proteins execute the majority of cellular function and their activity ultimately influences disease behaviour, proteomics represents a refined approach to investigating the role of GSCs in GBMs. To date, an extensive, comparative analysis of the GBM and GSC proteomes with parallel populations of normal neural stem cells has yet to be completed. By using an optimized MS workflow, I will conduct a thorough screen to identify the proteins and pathways critical to GBM and GSC growth. These protein candidates will then be tested for their potential as therapeutic targets in independent validation experiments. Ultimately, this proposal aims to conduct an informative, protein-based analysis of GSCs in the context of GBMS to define new proteins and pathways for the development of more effective, GSC-specific therapies.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kao, Jennifer
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~